New drug aims to protect kidneys in IgA nephropathy patients
NCT ID NCT07582133
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests the long-term safety of HRS-5965 capsules in 380 adults with primary IgA nephropathy, a kidney disease. Participants will take the drug and be monitored for side effects, as well as changes in urine protein and kidney function. The goal is to see if HRS-5965 can safely reduce kidney damage over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-5965 capsules
What this could lead to
If successful, this could provide a new treatment option to slow kidney damage and delay the need for dialysis or transplant in people with IgA nephropathy.
What could go wrong
This is an early-phase, open-label trial with no placebo group, so results may not confirm effectiveness. Long-term safety is still unknown, and the drug may cause side effects or fail to outperform existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, 100000, China
Contact